Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Status:
Recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for rare
genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant
histology, adrenocortical carcinoma, other rare genitourinary carcinomas and any
genitourinary carcinoma with neuroendocrine differentiation. Given preliminary results, the
study is being tested in additional patients with bladder or upper tract carcinoma with
variant histology at this time while the adrenocortical carcinoma, other rare genitourinary
malignancies arms have closed to accrual
-The names of the study drugs involved in this study are:
- Nivolumab
- Ipilimumab